Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Mar;7(Suppl 1):S7.
doi: 10.21037/atm.2019.01.37.

Blocking the PD-1/PD-L1 axis in advanced prostate cancer: are we moving in the right direction?

Andre P Fay  1   2 , Emmanuel S Antonarakis  3   4
Affiliations
Editorial

Blocking the PD-1/PD-L1 axis in advanced prostate cancer: are we moving in the right direction?

Andre P Fay et al. Ann Transl Med. 2019 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: Dr. Fay: advisory role for Novartis, Roche, Ipsen and MSD; honoraria from Astrazeneca, Bristol-Myers Squibb, Pfizer, Novartis, Roche, Astellas, MSD; Clinical research funding: Bristol-Myers Squibb, Roche, Astrazeneca, MSD, Pfizer. Dr. Antonarakis: consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Medivation, ESSA, AstraZeneca, Amgen, Clovis, and Merck; has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol Myers-Squibb, AstraZeneca, Celgene, Clovis, and Merck; and is the co-inventor of a biomarker technology that has been licensed to Qiagen.

Comment in

Comment on

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30. 10.3322/caac.21442 - DOI - PubMed
    1. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48. 10.1056/NEJMoa1209096 - DOI - PMC - PubMed
    1. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22. 10.1056/NEJMoa1001294 - DOI - PubMed
    1. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54. 10.1016/S0140-6736(10)61389-X - DOI - PubMed
    1. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97. 10.1056/NEJMoa1207506 - DOI - PubMed